Huang, B.T., Li, K.F., Wu, X.S., Zhang, F.Y. and Li, Y.P. (2025) Application and Research Advancement of Antibody-Conjugated Drugs in Non-Small Cell Lung Cancer. Journal of Biosciences and Medicines, ...

LAVAL, QC - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a pharmaceutical company with a market capitalization of $2.81 ...

The alpha blocker is typically prescribed to manage a nuisance symptom. Here's why the FDA says patients and healthcare ...

U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drive ...

Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes.

XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea ...

Recently in 2024, the agency received a report involving a patient who received the nasal solution as an injection.

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

A private business has helped supercharge a controversial federal drug program. Patients and insurers have been left with big bills. By Ellen Gabler Soon after being diagnosed with metastatic ...

US FDA approves Incyte and Syndax’s Niktimvo 9 mg & 22 mg vial sizes to treat chronic graft-versus-host disease: Wilmington, Delaware Friday, January 17, 2025, 13:30 Hrs [IST] I ...

drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...